Drug resistance in antiviral treatment for infections with hepatitis B and C viruses (Q36832325)

16 August 2017

1 reference

title

Drug resistance in antiviral treatment for infections with hepatitis B and C viruses (English)

1 reference

16 August 2017

2

Kazuhiko Koike

1 reference

16 August 2017

Hiroshi Yotsuyanagi

1

1 reference

PubMed ID

17530355

16 August 2017

language of work or name

1 reference

25 May 2007

1 reference

Journal of Gastroenterology

16 August 2017

1 reference

16 August 2017

42

1 reference

16 August 2017

5

1 reference

16 August 2017

329-335

1 reference

The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus

16 August 2017

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-007-2034-Z

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy

21 January 2018

1 reference

12 December 2020

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

12 December 2020

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Antiviral therapy for chronic hepatitis C: past, present, and future

1 reference

12 December 2020

Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment

1 reference

12 December 2020

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

12 December 2020

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

12 December 2020

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

12 December 2020

Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus

1 reference

12 December 2020

Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

1 reference

12 December 2020

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.

1 reference

12 December 2020

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

12 December 2020

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

1 reference

12 December 2020

Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.

1 reference

12 December 2020

Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients

1 reference

12 December 2020

Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.

1 reference

12 December 2020

Response to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence.

1 reference

12 December 2020

A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.

1 reference

12 December 2020

Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in taiwan: A comparison among asymptomatic carriers, Chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma

1 reference

12 December 2020

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy

1 reference

12 December 2020

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

1 reference

12 December 2020

The NS5a gene of hepatitis C virus in patients treated with interferon-alpha

1 reference

12 December 2020

ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.

1 reference

12 December 2020

NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients

1 reference

12 December 2020

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

1 reference

12 December 2020

Variant of hepatitis B virus with primary resistance to adefovir

1 reference

12 December 2020

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

12 December 2020

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

1 reference

12 December 2020

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

12 December 2020

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

12 December 2020

Symposium on clinical aspects in hepatitis virus infection. 1. Hepatitis viruses update

1 reference

12 December 2020

Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants

1 reference

12 December 2020

Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection

1 reference

12 December 2020

The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection.

1 reference

12 December 2020

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

1 reference

12 December 2020

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

12 December 2020

Global challenges in liver disease

1 reference

12 December 2020

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

12 December 2020

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

12 December 2020

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.

1 reference

12 December 2020

Update of research and management of hepatitis B.

1 reference

12 December 2020

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection

1 reference

12 December 2020

Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group.

1 reference

12 December 2020

10.1007/S00535-007-2034-Z

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17530355